You searched for adolescent%20medicine - Page 3 of 19 - Children's Hospital of Orange County

You searched for adolescent%20medicine.

Page 3 of 460 results

ADVL1615, A Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors

Clinical Trial Protocol # ADVL1615 | Adolescents and Young Adults, Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

https://www.choc.org/clinical-trials/advl1615-a-phase-1-study-of-pevonedistat-mln4924-ind-136078-a-nedd8-activating-enzyme-nae-inhibitor-in-combination-with-temozolomide-and-irinotecan-in-pediatric-patients-with-recurrent-or-ref/

Oncology Clinical Trial: Study of Kidney Tumors in Younger Patients

Clinical Trial Protocol # AREN03B2 | Biology/Genomics, Registry | Contact (714) 509-8646

https://www.choc.org/clinical-trials/oncology-clinical-trials/study-of-kidney-tumors-in-younger-patients/

Ba’Gah, Rebecca MD

Dr. Ba'Gah is board certified in child and adolescent psychiatry who treats kids and teens at CHOC Hospital in Orange.

https://www.choc.org/providers/psychiatry/rebecca-bagah-md/

ADVL1513, A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors and Lymphoma

Clinical Trial Protocol # ADVL1513 | Adolescents and Young Adults, Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

https://www.choc.org/clinical-trials/advl1513-a-phase-1-study-of-entinostat-an-oral-histone-deacetylase-inhibitor-in-pediatric-patients-with-recurrent-or-refractory-solid-tumors-including-cns-tumors-and-lymphoma/

Oncology Clinical Trial: WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Clinical Trial Protocol # ADVL1312 | Adolescents and Young Adults, Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

https://www.choc.org/clinical-trials/oncology-clinical-trials/wee1-inhibitor-mk-1775-and-irinotecan-hydrochloride-in-treating-younger-patients-with-relapsed-or-refractory-solid-tumors/

Oncology Clinical Trial: A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)

Clinical Trial Protocol # MK3475-051/ADVL1621 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

https://www.choc.org/clinical-trials/oncology-clinical-trials/a-study-of-pembrolizumab-mk-3475-in-pediatric-participants-with-advanced-melanoma-or-advanced-relapsed-or-refractory-pd-l1-positive-solid-tumors-or-lymphoma-mk-3475-051keynote-051/

AALL1521, A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK PathwayMutant Acute Lymphoblastic Leukemia

Clinical Trial Protocol # AALL1521 | Adolescents and Young Adults, Leukemia | Contact (714) 509-8646

https://www.choc.org/clinical-trials/aall1521-a-phase-2-study-of-the-jak1jak2-inhibitor-ruxolitinib-with-chemotherapy-in-children-with-de-novo-high-risk-crlf2-rearranged-andor-jak-pathwaymutant-acute-lymphoblastic-leukemia/

Oncology Clinical Trial: Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas

Clinical Trial Protocol # ALTE11C1 | Adolescents and Young Adults, Fertility, Survivorship | Contact (714) 509-8646

https://www.choc.org/clinical-trials/oncology-clinical-trials/blood-sample-markers-of-reproductive-hormones-in-assessing-ovarian-reserve-in-younger-patients-with-newly-diagnosed-lymphomas/

Phase 1/2 Study of Lenvatinib in Combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, including CNS

Clinical Trial Protocol # ADVL1711 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

https://www.choc.org/clinical-trials/a-phase-12-study-of-lenvatinib-in-combination-with-everolimus-in-recurrent-and-refractory-pediatric-solid-tumors-including-cns/

Phase 1 Study of Pevonedistat (MLN4924, IND# 136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors

Clinical Trial Protocol # ADVL1615 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

https://www.choc.org/clinical-trials/a-phase-1-study-of-pevonedistat-mln4924-ind-136078-a-nedd8-activating-enzyme-nae-inhibitor-in-combination-with-temozolomide-and-irinotecan-in-pediatric-patients-with-recurrent-or-refractory-so/

Oncology Clinical Trial: WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Clinical Trial Protocol # ADVL1217 | Brain Tumor/Central Nervous System/Neuro-Oncology | Contact (714) 509-8646

https://www.choc.org/clinical-trials/oncology-clinical-trials/wee1-inhibitor-mk-1775-and-local-radiation-therapy-in-treating-younger-patients-with-newly-diagnosed-diffuse-intrinsic-pontine-gliomas/

Oncology Clinical Trial: Study of a Tool for Advanced Care Planning in Young Adults Cancer and Other Life Threatening Illnesses

Clinical Trial | Adolescents and Young Adults, Recurrent/Refractory Cancer, Supportive Care, Survivorship | Contact (714) 509-8646

https://www.choc.org/clinical-trials/oncology-clinical-trials/study-of-a-tool-for-advanced-care-planning-in-young-adults-cancer-and-other-life-threatening-illnesses/

Oncology Clinical Trial: Pazopanib Paediatric Phase II Trial Children’s Oncology Group (COG) in Solid Tumors

Clinical Trial Protocol # ADVL1322 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

https://www.choc.org/clinical-trials/oncology-clinical-trials/pazopanib-paediatric-phase-ii-trial-childrens-oncology-group-cog-in-solid-tumors/

Oncology Clinical Trial: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Clinical Trial Protocol # AALL1331 | Leukemia/Lymphoma, Recurrent/Refractory Cancer | Contact (714) 509-8646

https://www.choc.org/clinical-trials/oncology-clinical-trials/blinatumomab-in-treating-younger-patients-with-relapsed-b-cell-acute-lymphoblastic-leukemia/

A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)

Clinical Trial Protocol # ADVL1621 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

https://www.choc.org/clinical-trials/a-phase-iii-study-of-pembrolizumab-mk-3475-in-children-with-advanced-melanoma-or-a-pd-l1-positive-advanced-relapsed-or-refractory-solid-tumor-or-lymphoma-keynote-051/

Oncology Clinical Trial: Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

Clinical Trial Protocol # ADVL1412 | Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

https://www.choc.org/clinical-trials/oncology-clinical-trials/nivolumab-with-or-without-ipilimumab-in-treating-younger-patients-with-recurrent-or-refractory-solid-tumors-or-sarcomas/

Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors

Clinical Trial Protocol # ADVL1622 | Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

https://www.choc.org/clinical-trials/phase-2-trial-of-xl184-cabozantinib-an-oral-small-molecule-inhibitor-of-multiple-kinases-in-children-and-young-adults-with-refractory-sarcomas-wilms-tumor-and-other-rare-tumors/

ADVL1515 A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors

Clinical Trial Protocol # ADVL1515 | Adolescents and Young Adults, Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors | Contact (714) 509-8646

https://www.choc.org/clinical-trials/advl1515-a-phase-1-study-of-ly2606368-a-chk1-2-inhibitor-in-pediatric-patients-with-recurrent-or-refractory-solid-tumors-including-cns-tumors/

An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects > 1 and < 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Clinical Trial Protocol # JNJ-54767414 | Adolescents and Young Adults, Leukemia/Lymphom, Recurrent/Refractory Cancer | Contact (714) 509-8646

https://www.choc.org/clinical-trials/oncology-clinical-trials/an-open-label-multicenter-phase-2-study-evaluating-the-efficacy-and-safety-of-daratumumab-in-pediatric-and-young-adult-subjects-1-and-30-years-of-age-with-relapsed-refractory-precursor-b-cell-or/